Michael Harrop
Well-known member
https://www.reuters.com/legal/litigation/finch-wins-us-jury-trial-against-ferring-over-fecal-transplant-patents-2024-08-09/
Interesting.
Rebyota, a rectally delivered product developed by Ferring Pharmaceuticals, that secured FDA approval in November 2022.
Interesting.
Rebyota, a rectally delivered product developed by Ferring Pharmaceuticals, that secured FDA approval in November 2022.
The jury agreed with Finch that Ferring's fecal-transplant therapy Rebyota infringes patents covering related inventions that Finch licensed from the university.
A federal jury in Delaware said on Friday that Swiss biopharmaceutical company Ferring Pharmaceuticals infringed patents for fecal transplant technology belonging to Finch Therapeutics (FNCH.PK), and the University of Minnesota, and should pay $25 million in damages and future royalties.
Ferring argued in the case that its technology worked differently than Finch's and that the three patents at issue in the trial were invalid.
- Format correct?
- Yes
Last edited: